Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MAPRE1
REST API REST API
Homo sapiens
MAPRE1 is differentially expressed in 289 experiments: 134 organism parts: liver, lung, ... (132 more);, 226 disease states: normal, acute lymphoblastic leukemia, ... (224 more);, 87 cell types 390 cell lines 36 compound treatments and 71 other conditions.
Synonyms EB1
Orthologs Mapre1 (Mus musculus)   Mapre1 (Rattus norvegicus)   MARE1_CHICK (Gallus gallus)   BIM1 (Saccharomyces cerevisiae)   MAPRE1 (Bos taurus)   mapre1l (Danio rerio)   CG18190 (Drosophila melanogaster)   CG32371 (Drosophila melanogaster)   CG31907 (Drosophila melanogaster)   Eb1 (Drosophila melanogaster)   CG2955 (Drosophila melanogaster)   CG15306 (Drosophila melanogaster)   mapre1 (Xenopus laevis)   LOC606844 (Canis familiaris)   XP_851284.1 (Canis familiaris)   ENSCAFG00000017212 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, microtubule plus-end binding, cell division, M phase of mitotic cell cycle, microtubule binding, protein binding, cytoskeleton, cytoplasm, cell proliferation, mitotic cell cycle, Golgi apparatus, mitotic prometaphase, centrosome, spindle, microtubule, cell projection, G2/M transition of mitotic cell cycle, cytoplasmic microtubule, protein C-terminus binding, protein localization to microtubule, cell projection membrane, negative regulation of microtubule polymerization, cortical microtubule cytoskeleton
InterPro Term EB1_C, CH-domain
UniProt Accession Q15691
Search EB-eye ENSG00000101367
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-1577, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (36 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
H1437
2
E-GEOD-16194, E-MTAB-62
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
HT1080
2
E-MTAB-37, E-GEOD-20089
MCF-7
2
E-GEOD-20081, E-GEOD-3529
MDA-MB-231
2
E-TABM-420, E-MTAB-62
384 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-MEXP-750, ... (40 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
monocyte
1
2
E-GEOD-22373, E-GEOD-5099, E-GEOD-8286
wild_type
1
E-GEOD-20193
parental foreskin cells
1
E-GEOD-20033
CXCR4 negative
1
E-GEOD-15893
81 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-MTAB-62, ... (64 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-GEOD-6014
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
prostate carcinoma
2
E-GEOD-96, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-GEOD-3726, E-MTAB-62
220 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5258, E-GEOD-5824, E-MEXP-1958, ... (26 experiments)

Factor Value U/D Experiments
none
4
7
E-GEOD-5824, E-GEOD-412, E-MEXP-1958, E-GEOD-2803, E-GEOD-20719, ... (11 experiments)
dimethyl sulfoxide
2
E-GEOD-5824, E-GEOD-6932
valproic acid
1
E-GEOD-1615
TTA
1
E-MEXP-2590
unknown
1
E-GEOD-7307
Cxcl12
1
E-GEOD-7307
30 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-22148, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-6207, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-GEOD-18005, E-TABM-601, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-3720, E-GEOD-1926, ... (35 experiments)

Infection
studied in E-MEXP-1274, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Stimulus or stress
studied in E-GEOD-7538

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-6532, E-GEOD-4922

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.33 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM